Ozagrel Sodium Injection

This product is a thromboxane (TX) synthase inhibitor, which can inhibit the generation of thromboxane A2 (TXA2) from prostaglandin H2 (PGH2), and promote the transfer of PGH2 derived from platelets to endothelial cells. Endothelial cells are used to synthesize PGI2, thereby improving the abnormal balance between TXA2 and prostaglandin PGI2. Theoretically, it can inhibit platelet aggregation and vasodilation. This product can improve movement disorders in the acute stage of cerebral thrombosis, improve circulatory disorders in the acute stage of cerebral ischemia, and improve abnormal energy metabolism during cerebral ischemia. Animal experiments have shown that intravenous administration can reduce plasma TXB2 levels, increase the ratio of 6-Keto-PGF1a/TXB2, inhibit platelet aggregation caused by different inducers, and prevent cerebral infarction caused by middle cerebral artery occlusion in rats. The half-maximal inhibitory concentration IC50 of this product for human platelet aggregation is low, at 4nM. Experiments using autologous blood injected into the subarachnoid hemorrhage model showed that continuous intravenous injection of this product has the effects of inhibiting blood TXB2 concentration and cerebral vasoconstriction.

Ozagrel sodium. Excipients: glycine, citric acid, sodium chloride, sodium oxychloride.

This product is a colorless clear liquid.

Used to treat acute thrombotic cerebral infarction and movement disorders associated with cerebral infarction, and to improve cerebral vasospasm and contraction and concurrent cerebral ischemia symptoms after subarachnoid hemorrhage surgery.

Adults: 80 mg each time, dissolved in an appropriate amount of electrolytes or 5% glucose solution, twice a day, continuous intravenous drip, 2 weeks as a course of treatment. In addition, the dosage can be appropriately increased or decreased according to age and symptoms.

Blood: Due to the tendency of bleeding, observe carefully and stop the administration immediately if abnormalities occur. Liver and kidney: Occasionally, GOT, GPT, and BUN may increase. Digestive system: Occasionally, there may be nausea, vomiting, diarrhea, loss of appetite, and a feeling of fullness. Allergic reactions: Occasionally, urticaria and rash may occur. Stop the administration when they occur. Circulatory system: Occasionally, there may be supraventricular arrhythmia and a decrease in blood pressure. When found, reduce the dose or stop the administration. Others: Occasionally, there may be headache, fever, pain at the injection site, shock, and thrombocytopenia. Serious adverse reactions may include hemorrhagic cerebral infarction, epidural hematoma, intracerebral hemorrhage, gastrointestinal bleeding, subcutaneous bleeding, etc.

1. Those who are allergic to this product; 2. Those with cerebral hemorrhage or cerebral infarction and bleeding; 3. Those with severe heart, lung, liver, and kidney dysfunction, such as severe arrhythmia; 4. Those with blood diseases or bleeding tendencies; 5. Those with severe hypertension, with systolic blood pressure exceeding 26.6kpa (i.e. 200mmHg).

Precautions for children: Use with caution in children. Precautions for pregnancy and lactation: Use with caution in pregnant women or women who may become pregnant. Precautions for the elderly: This experiment has not been conducted and there is no reliable reference literature.

This experiment has not been conducted and there are no reliable references.

Keep away from light and store in a sealed container.

4ml:80mg

36 months.

Changchun Extrawell Pharmaceutical Co., Ltd.

• Founded in:

  1992-08-08

• Address:

  No. 538, Tongyou Road, Industrial North District, Jiutai Economic Development Zone, Changchun

• Tax NO.:

  91220000605118490G

• Registered Funds:

  45.43 million yuan

• Website:

  Log in to view

• Email:

  Log in to view